Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

被引:1581
作者
Molina, Daniel Martinez [1 ]
Jafari, Rozbeh [1 ]
Ignatushchenko, Marina [1 ]
Seki, Takahiro [2 ]
Larsson, E. Andreas [3 ]
Dan, Chen [3 ]
Sreekumar, Lekshmy [3 ]
Cao, Yihai [2 ,4 ]
Nordlund, Par [1 ,3 ]
机构
[1] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden
[2] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden
[3] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore
[4] Linkoping Univ, Dept Med & Hlth Sci, S-58183 Linkoping, Sweden
基金
欧洲研究理事会; 瑞典研究理事会;
关键词
KINASE INHIBITORS; PROTEIN STABILITY; PHASE-I; CANCER; RESISTANCE; PARP; PHARMACOKINETICS; SUPPRESSION; MECHANISMS; DISCOVERY;
D O I
10.1126/science.1233606
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The efficacy of therapeutics is dependent on a drug binding to its cognate target. Optimization of target engagement by drugs in cells is often challenging, because drug binding cannot be monitored inside cells. We have developed a method for evaluating drug binding to target proteins in cells and tissue samples. This cellular thermal shift assay (CETSA) is based on the biophysical principle of ligand-induced thermal stabilization of target proteins. Using this assay, we validated drug binding for a set of important clinical targets and monitored processes of drug transport and activation, off-target effects and drug resistance in cancer cell lines, as well as drug distribution in tissues. CETSA is likely to become a valuable tool for the validation and optimization of drug target engagement.
引用
收藏
页码:84 / 87
页数:4
相关论文
共 36 条
[21]   Large-scale prediction and testing of drug activity on side-effect targets [J].
Lounkine, Eugen ;
Keiser, Michael J. ;
Whitebread, Steven ;
Mikhailov, Dmitri ;
Hamon, Jacques ;
Jenkins, Jeremy L. ;
Lavan, Paul ;
Weber, Eckhard ;
Doak, Allison K. ;
Cote, Serge ;
Shoichet, Brian K. ;
Urban, Laszlo .
NATURE, 2012, 486 (7403) :361-+
[22]   Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction [J].
Luo, Ji ;
Solimini, Nicole L. ;
Elledge, Stephen J. .
CELL, 2009, 136 (05) :823-837
[23]   Cell cycle, CDKs and cancer: a changing paradigm [J].
Malumbres, Marcos ;
Barbacid, Mariano .
NATURE REVIEWS CANCER, 2009, 9 (03) :153-166
[24]   Thymidylate synthase pharmacogenetics [J].
Marsh, S .
INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) :533-537
[25]   Positron emission tomography molecular imaging for drug development [J].
Matthews, Paul M. ;
Rabiner, Eugenii A. ;
Passchier, Jan ;
Gunn, Roger N. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) :175-186
[26]   Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma [J].
Moore, JD ;
Dezube, BJ ;
Gill, P ;
Zhou, XJ ;
Acosta, EP ;
Sommadossi, JP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (03) :173-179
[27]   A GUIDE TO DRUG DISCOVERY - OPINION The future of drug development: advancing clinical trial design [J].
Orloff, John ;
Douglas, Frank ;
Pinheiro, Jose ;
Levinson, Susan ;
Branson, Michael ;
Chaturvedi, Pravin ;
Ette, Ene ;
Gallo, Paul ;
Hirsch, Gigi ;
Mehta, Cyrus ;
Patel, Nitin ;
Sabir, Sameer ;
Springs, Stacy ;
Stanski, Donald ;
Evers, Matthias R. ;
Fleming, Edd ;
Singh, Navjot ;
Tramontin, Tony ;
Golub, Howard .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (12) :949-957
[28]   Trends in the exploitation of novel drug targets [J].
Rask-Andersen, Mathias ;
Almen, Markus Sallman ;
Schioth, Helgi B. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (08) :579-590
[29]   Pharmacokinetics in drug discovery [J].
Ruiz-Garcia, Ana ;
Bermejo, Marival ;
Moss, Aaron ;
Casabo, Vicente G. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (02) :654-690
[30]   GSK/Sirtris compounds dogged by assay artifacts [J].
Schmidt, Charlie .
NATURE BIOTECHNOLOGY, 2010, 28 (03) :185-186